Terms ending in 2043
Every in-force patent on Ablynx N.V.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,384,840 | Nucleic Acids Encoding Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting IL-13 and TSLP In force · Medium confidence | N.V., Ablynx | In force | Medium confidence | |
| US 12,479,885 | Chromatography-Free Antibody Purification Method In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 12,528,860 | Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting Tnfa and IL-23 In force · Medium confidence | Sanofi | In force | Medium confidence | |
| US 12,492,248 | Methods of Treatment Utilizing Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting IL-13 and TSLP In force · Medium confidence | N.V., Ablynx | In force | Medium confidence | |
| US 12,195,546 | CD28/OX40 Bispecific Antibodies In force · High confidence | Sanofi | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Ablynx N.V..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.